How Imaging Can Impact Clinical Trial Design

作者: David A. Mankoff , Michael D. Farwell , Amy S. Clark , Daniel A. Pryma

DOI: 10.1097/PPO.0000000000000116

关键词:

摘要: The ability to measure biochemical and molecular processes guide cancer treatment represents a potentially powerful tool for trials of targeted therapy. These assays have traditionally been performed by analysis tissue samples. However, more recently, functional imaging has developed that is capable in vivo biochemistry biology highly complementary tissue-based assays. Cancer biomarkers can play key role increasing the efficacy efficiency therapeutic clinical also provide insight into biologic mechanisms bring about response. Future progress will depend on close collaboration between scientists physicians public commercial sponsors, take full advantage what offer This review examples how inform decision making (1) measuring regional expression target, (2) assessing early (pharmacodynamic) response treatment, (3) predicting outcome. includes discussion basic principles cancer, with an emphasis those methods tested patients. We then designed evaluate tests as integrated markers embedded trial goal validating integral aid patient selection direct response-adapted strategies. Examples recently completed multicenter using are highlighted.

参考文章(41)
Joanne E. Mortimer, Farrokh Dehdashti, Barry A. Siegel, Kathryn Trinkaus, John A. Katzenellenbogen, Michael J. Welch, Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. Journal of Clinical Oncology. ,vol. 19, pp. 2797- 2803 ,(2001) , 10.1200/JCO.2001.19.11.2797
James M. Mountz, Thomas E. Yankeelov, Daniel L. Rubin, John M. Buatti, Bradley J. Erikson, Fiona M. Fennessy, Robert J. Gillies, Wie Huang, Michael A. Jacobs, Paul E. Kinahan, Charles M. Laymon, Hannah M. Linden, David A. Mankoff, Lawrence H. Schwartz, Hyunsuk Shim, Richard L. Wahl, Letter to Cancer Center Directors: Progress in Quantitative Imaging As a Means to Predict and/or Measure Tumor Response in Cancer Therapy Trials Journal of Clinical Oncology. ,vol. 32, pp. 2115- 2116 ,(2014) , 10.1200/JCO.2014.55.8866
L. M. Peterson, D. A. Mankoff, T. Lawton, K. Yagle, E. K. Schubert, S. Stekhova, A. Gown, J. M. Link, T. Tewson, K. A. Krohn, Quantitative Imaging of Estrogen Receptor Expression in Breast Cancer with PET and 18F-Fluoroestradiol The Journal of Nuclear Medicine. ,vol. 49, pp. 367- 374 ,(2008) , 10.2967/JNUMED.107.047506
Robert K. Doot, Elizabeth S. McDonald, David A. Mankoff, Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials. Clinical and Translational Imaging. ,vol. 2, pp. 295- 303 ,(2014) , 10.1007/S40336-014-0071-1
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026
Lalitha K. Shankar, The clinical evaluation of novel imaging methods for cancer management Nature Reviews Clinical Oncology. ,vol. 9, pp. 738- 744 ,(2012) , 10.1038/NRCLINONC.2012.186
Farrokh Dehdashti, Joanne E. Mortimer, Kathryn Trinkaus, Michael J. Naughton, Matthew Ellis, John A. Katzenellenbogen, Michael J. Welch, Barry A. Siegel, PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer Breast Cancer Research and Treatment. ,vol. 113, pp. 509- 517 ,(2009) , 10.1007/S10549-008-9953-0
Laura Kenny, R. Charles Coombes, David M. Vigushin, Adil Al-Nahhas, Sami Shousha, Eric O. Aboagye, Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography European Journal of Nuclear Medicine and Molecular Imaging. ,vol. 34, pp. 1339- 1347 ,(2007) , 10.1007/S00259-007-0379-4
John P. Leonard, Ann S. LaCasce, Mitchell R. Smith, Ariela Noy, Lucian R. Chirieac, Scott J. Rodig, Jian Q. Yu, Shankar Vallabhajosula, Heiko Schoder, Patricia English, Donna S. Neuberg, Peter Martin, Michael M. Millenson, Scott A. Ely, Rachel Courtney, Naveed Shaik, Keith D. Wilner, Sophia Randolph, Annick D. Van den Abbeele, Selina Y. Chen-Kiang, Jeffrey T. Yap, Geoffrey I. Shapiro, Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma Blood. ,vol. 119, pp. 4597- 4607 ,(2012) , 10.1182/BLOOD-2011-10-388298